Long term response in a patient with neoplastic meningitis secondary to melanoma treated with 131I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab′)2: A case study

Ilkcan Cokgor; Gamal Akabani; Henry S. Friedman; Allan H. Friedman; Michael R. Zalutsky; Lee M. Zehngebot; James M. Provenzale; Cynthia D. Guy; Carol J. Wikstrand; Darell D. Bigner

doi:10.1002/1097-0142(20010501)91:9<1809::AID-CNCR1200>3.0.CO;2-L

Long term response in a patient with neoplastic meningitis secondary to melanoma treated with ¹³¹I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab′)₂: A case study

Ilkcan Cokgor, Gamal Akabani, Henry S. Friedman, Allan H. Friedman, Michael R. Zalutsky, Lee M. Zehngebot, James M. Provenzale, Cynthia D. Guy, Carol J. Wikstrand, Darell D. Bigner

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Even with novel chemotherapeutic agents and external beam radiation therapy, the prognosis of neoplastic meningitis secondary to malignant melanoma is still dismal. The authors report a case study of a 46-year-old white female who presented with progressive hearing loss, severe headaches, nausea, vomiting, and a rapid decline in neurologic status. She was referred to Duke University Medical Center after conventional chemotherapy for malignant melanoma failed. She was enrolled in a Phase I trial of ¹³¹I-labeled monoclonal antibody Mel-14 F(ab′)₂ fragment administered intrathecally. Within a year after her treatment, she recovered, having a normal neurologic exam except for residual bilateral hearing loss. The authors discuss dosimetry, preclinical, and clinical studies conducted with Mel-14 F(ab′)₂ and introduce a potentially promising therapy option in the treatment of neoplastic meningitis in patients with malignant melanoma. Currently, the patient remains neurologically normal except for a mild bilateral hearing loss more than 4 years after treatment and has no radiographic evidence of neoplastic meningitis.

Original language	English
Pages (from-to)	1809-1813
Number of pages	5
Journal	Cancer
Volume	91
Issue number	9
DOIs	https://doi.org/10.1002/1097-0142(20010501)91:9<1809::AID-CNCR1200>3.0.CO;2-L
State	Published - 1 May 2001
Externally published	Yes

Keywords

I
Malignant melanoma
Mel-14 F(ab′)
Monoclonal antibody
Neoplastic meningitis
Treatment

Access to Document

10.1002/1097-0142(20010501)91:9<1809::AID-CNCR1200>3.0.CO;2-L

Cite this

Cokgor, I., Akabani, G., Friedman, H. S., Friedman, A. H., Zalutsky, M. R., Zehngebot, L. M., Provenzale, J. M., Guy, C. D., Wikstrand, C. J., & Bigner, D. D. (2001). Long term response in a patient with neoplastic meningitis secondary to melanoma treated with ¹³¹I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab′)₂: A case study. Cancer, 91(9), 1809-1813. https://doi.org/10.1002/1097-0142(20010501)91:9<1809::AID-CNCR1200>3.0.CO;2-L

@article{25d2e07d78344b959d99f374cb991a73,

title = "Long term response in a patient with neoplastic meningitis secondary to melanoma treated with 131I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab′)2: A case study",

abstract = "Even with novel chemotherapeutic agents and external beam radiation therapy, the prognosis of neoplastic meningitis secondary to malignant melanoma is still dismal. The authors report a case study of a 46-year-old white female who presented with progressive hearing loss, severe headaches, nausea, vomiting, and a rapid decline in neurologic status. She was referred to Duke University Medical Center after conventional chemotherapy for malignant melanoma failed. She was enrolled in a Phase I trial of 131I-labeled monoclonal antibody Mel-14 F(ab′)2 fragment administered intrathecally. Within a year after her treatment, she recovered, having a normal neurologic exam except for residual bilateral hearing loss. The authors discuss dosimetry, preclinical, and clinical studies conducted with Mel-14 F(ab′)2 and introduce a potentially promising therapy option in the treatment of neoplastic meningitis in patients with malignant melanoma. Currently, the patient remains neurologically normal except for a mild bilateral hearing loss more than 4 years after treatment and has no radiographic evidence of neoplastic meningitis.",

keywords = "I, Malignant melanoma, Mel-14 F(ab′), Monoclonal antibody, Neoplastic meningitis, Treatment",

author = "Ilkcan Cokgor and Gamal Akabani and Friedman, {Henry S.} and Friedman, {Allan H.} and Zalutsky, {Michael R.} and Zehngebot, {Lee M.} and Provenzale, {James M.} and Guy, {Cynthia D.} and Wikstrand, {Carol J.} and Bigner, {Darell D.}",

year = "2001",

month = may,

day = "1",

doi = "10.1002/1097-0142(20010501)91:9<1809::AID-CNCR1200>3.0.CO;2-L",

language = "English",

volume = "91",

pages = "1809--1813",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley & Sons Inc.",

number = "9",

}

Cokgor, I, Akabani, G, Friedman, HS, Friedman, AH, Zalutsky, MR, Zehngebot, LM, Provenzale, JM, Guy, CD, Wikstrand, CJ & Bigner, DD 2001, 'Long term response in a patient with neoplastic meningitis secondary to melanoma treated with ¹³¹I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab′)₂: A case study', Cancer, vol. 91, no. 9, pp. 1809-1813. https://doi.org/10.1002/1097-0142(20010501)91:9<1809::AID-CNCR1200>3.0.CO;2-L

TY - JOUR

T1 - Long term response in a patient with neoplastic meningitis secondary to melanoma treated with 131I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab′)2

T2 - A case study

AU - Cokgor, Ilkcan

AU - Akabani, Gamal

AU - Friedman, Henry S.

AU - Friedman, Allan H.

AU - Zalutsky, Michael R.

AU - Zehngebot, Lee M.

AU - Provenzale, James M.

AU - Guy, Cynthia D.

AU - Wikstrand, Carol J.

AU - Bigner, Darell D.

PY - 2001/5/1

Y1 - 2001/5/1

N2 - Even with novel chemotherapeutic agents and external beam radiation therapy, the prognosis of neoplastic meningitis secondary to malignant melanoma is still dismal. The authors report a case study of a 46-year-old white female who presented with progressive hearing loss, severe headaches, nausea, vomiting, and a rapid decline in neurologic status. She was referred to Duke University Medical Center after conventional chemotherapy for malignant melanoma failed. She was enrolled in a Phase I trial of 131I-labeled monoclonal antibody Mel-14 F(ab′)2 fragment administered intrathecally. Within a year after her treatment, she recovered, having a normal neurologic exam except for residual bilateral hearing loss. The authors discuss dosimetry, preclinical, and clinical studies conducted with Mel-14 F(ab′)2 and introduce a potentially promising therapy option in the treatment of neoplastic meningitis in patients with malignant melanoma. Currently, the patient remains neurologically normal except for a mild bilateral hearing loss more than 4 years after treatment and has no radiographic evidence of neoplastic meningitis.

AB - Even with novel chemotherapeutic agents and external beam radiation therapy, the prognosis of neoplastic meningitis secondary to malignant melanoma is still dismal. The authors report a case study of a 46-year-old white female who presented with progressive hearing loss, severe headaches, nausea, vomiting, and a rapid decline in neurologic status. She was referred to Duke University Medical Center after conventional chemotherapy for malignant melanoma failed. She was enrolled in a Phase I trial of 131I-labeled monoclonal antibody Mel-14 F(ab′)2 fragment administered intrathecally. Within a year after her treatment, she recovered, having a normal neurologic exam except for residual bilateral hearing loss. The authors discuss dosimetry, preclinical, and clinical studies conducted with Mel-14 F(ab′)2 and introduce a potentially promising therapy option in the treatment of neoplastic meningitis in patients with malignant melanoma. Currently, the patient remains neurologically normal except for a mild bilateral hearing loss more than 4 years after treatment and has no radiographic evidence of neoplastic meningitis.

KW - I

KW - Malignant melanoma

KW - Mel-14 F(ab′)

KW - Monoclonal antibody

KW - Neoplastic meningitis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0035340633&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20010501)91:9<1809::AID-CNCR1200>3.0.CO;2-L

DO - 10.1002/1097-0142(20010501)91:9<1809::AID-CNCR1200>3.0.CO;2-L

M3 - Article

C2 - 11335907

AN - SCOPUS:0035340633

SN - 0008-543X

VL - 91

SP - 1809

EP - 1813

JO - Cancer

JF - Cancer

IS - 9

ER -